



NOVA

University of Newcastle Research Online

nova.newcastle.edu.au

Liu, Hongpeng; Zhu, Dawei; Song, Baoyun; Jin, Jingfen; Liu, Yilan; Wen, Xianxiu; Cheng, Shouzhen; Nicholas, Stephen; Wu, Xinjuan. "Cost-effectiveness of an intervention to improve the quality of nursing care among immobile patients with stroke in China: a multicenter study". Published in *International Journal of Nursing Studies* Vol. 110, Issue October 2020, no. 103703 (2020).

Available from: <http://dx.doi.org/10.1016/j.ijnurstu.2020.103703>

© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
<http://creativecommons.org/licenses/by-nc-nd/4.0/>

Accessed from: <http://hdl.handle.net/1959.13/1431151>

1 **Title:** Cost-effectiveness of an intervention to improve the quality of nursing care
2 among immobile patients with stroke in China: A multicenter study

3 **Running title:** Cost-effectiveness of nursing intervention in immobile stroke patients
4 in China

5 Hongpeng Liu, MSN, RN^{1#}, Dawei Zhu, PhD^{2#}, Baoyun Song, RN³, Jingfen Jin, RN,
6 MSN⁴, Yilan Liu, RN, PhD⁵, Xianxiu Wen, RN⁶, Shouzhen Cheng, RN, MSN⁷, Stephen
7 Nicholas, PhD⁸⁻¹¹, Xinjuan Wu, RN, MSN^{1*}

8 1. Department of Nursing, Chinese Academy of Medical Sciences - Peking Union
9 Medical College, Peking Union Medical College Hospital (Dongdan campus),
10 No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing 100730, China.

11 2. China Center for Health Development Studies, Peking University, No.38, Xueyuan
12 Road, Haidian District, Beijing 100191, China.

13 3. Department of Nursing, Henan Provincial People's Hospital, No.7 Weiwu Road,
14 Jinshui District, Zhengzhou 450003, China.

15 4. The Second Affiliated Hospital Zhejiang University School of Medicine, No.88
16 Jiefang Road, Hangzhou 310009, China.

17 5. Department of Nursing, Wuhan Union Hospital, No.1277 Jiefangdadao, Jiangnan
18 District, Wuhan 430060, China.

19 6. Department of Nursing, Sichuan Provincial People's Hospital, No.32 West Second
20 Section First Ring Road, Chengdu 610072, China.

21 7. Department of Nursing, The First Affiliated Hospital, Sun Yat-sen University,
22 No.58 Zhongshan Second Road, Yuexiu District, Guangzhou 200032, China.

- 1 8. Australian National Institute of Management and Commerce, 1 Central Avenue Australian
2 Technology Park, Eveleigh Sydney NSW 2015, Australia.
- 3 9. School of Economics and School of Management, Tianjin Normal University, West
4 Bin Shui Avenue, Tianjin 300074, China.
- 5 10. Guangdong Institute for International Strategies, Guangdong University of Foreign
6 Studies, Baiyun Avenue North, Guangzhou 510420, China.
- 7 11. Newcastle Business School, University of Newcastle, University Drive, Newcastle,
8 NSW 2308, Australia.

9 #These authors contributed equally to this work.

10 ***Email of authors***

11 Hongpeng Liu: liuhongpeng12@sina.com

12 Dawei Zhu: zhu_dawei@163.com

13 Baoyun Song: baoyun8865@126.com

14 Jingfen Jin: zrjzkh1@zju.edu.cn

15 Yilan Liu: yilanl2008@sina.com

16 Xianxiu Wen: wxxjyc@163.com

17 Shouzhen Cheng: szcheng05@126.com

18 Stephen Nicholas: stephen.nicholas@newcastle.edu.au

19 Xinjuan Wu: wuxinjuan@sina.com

20 *Corresponding author: Xinjuan Wu, RN, MSN, Department of Nursing, Chinese
21 Academy of Medical Sciences - Peking Union Medical College, Peking Union Medical
22 College Hospital (Dongdan campus), No.1 Shuaifuyuan Wangfujing Dongcheng

1 District, Beijing 100730, China. Email: wuxinjuan@sina.com. Tel:(010) +86 69156114,

2 Fax: +86-010-6915-6114.

3 Funding/Support: This paper was supported by the National Health and Family

4 Planning Commission (Beijing, China) [grant numbers 201502017].

5 Word Count: 4854

6 Abstract: 366

7 Number of Pages: 35

8 Number of Figures: 2

9 Number of Tables: 4

10 Number of Supplemental Files: 1

11

12

13

14

15 **Title:** Cost-effectiveness of an intervention to improve the quality of nursing care
16 among immobile patients with stroke in China: A multicenter study

17 **Abstract**

18 *Background:* While a nursing intervention program for immobile patients with stroke
19 can improve clinic outcomes, less is known about the cost-effectiveness of these
20 interventions.

21 *Objectives:* The goal of this study was to evaluate the cost-effectiveness of the

1 intervention program for immobile patients with stroke in China.

2 *Design and Setting:* This is a pre-test/post-test (before and after) study. Participants
3 were recruited from six provinces or municipal cities in eastern (Guangdong province,
4 Zhejiang province, and Beijing municipal city), western (Sichuan province), and central
5 (Henan province and Hubei province) China.

6 *Participants:* A total of 7,653 immobile stroke patients were included in our sample.
7 Patients in routine care settings were recruited from November 2015 to June 2016, and
8 the recruitment of the intervention group patients was from November 2016 to July
9 2017.

10 *Methods:* To adjust for potential bias from confounding variables, the 1:1 propensity
11 score matching yielded matched pairs of 2,966 patients in the routine care group and
12 2,966 patients in the intervention group, with no significant differences in
13 sociodemographic or clinical characteristics between two groups. All patients were
14 followed-up 3 months after enrolment in the study. Total healthcare costs were extracted
15 from the hospital information system, with the health outcome effectiveness of the
16 intervention program measured using the EuroQol five-dimensional questionnaire (EQ-
17 5D) instrument and the cost-effectiveness of the intervention measured by the
18 incremental cost-effectiveness ratio with a time horizon of 3 months.

19 *Results:* Compared to routine care, the intervention program decreased the total costs
20 of stroke patients by CN¥4,600 (95% confidence interval [CI]: [-7050, -2151]), while
21 increasing quality-adjusted life year 0.009 (95% CI: [0.005, 0.013]). The incremental
22 cost-effectiveness ratios over 3 months was CN¥--517,011 per quality-adjusted life year

1 (95% CI: [-1111442, -203912]). Subgroup analysis reveals that both the health-related
2 quality of life and cost effectiveness improved significantly for ischemic patients and
3 tertiary hospitals patients while for hemorrhagic patients and non-tertiary hospital
4 patients only the health-related quality of life improved significantly.

5 *Conclusions:* Findings from this first cost-effectiveness analysis in immobile stroke
6 patients provide evidence that an intervention program provided significant cost saving,
7 but mainly in ischemic patients and tertiary hospital patients. Wider adoption of such
8 programs may be a sensible approach to reducing the burden of stroke and for immobile
9 patients more generally.

10 **What is already known about the topic?**

- 11 · Medical complications after stroke can increase the costs of health care and account
12 for a significant part of direct costs of stroke.
- 13 · A nursing intervention program can decrease the incidences of medical
14 complications (such as pressure injuries, pneumonia, deep vein thrombosis, and
15 urinary tract infections), less is known about the cost-effectiveness of these
16 interventions.
- 17 · Few cost-effectiveness analyses of nursing interventions for immobile stroke
18 patients have been undertaken in China.

19 **What this paper adds**

- 20 · A nursing intervention program for immobile stroke patients can save costs and are
21 also more effective in health-related quality of life outcomes for immobile stroke
22 patients than routine care.

1 · Both the health-related quality of life and cost effectiveness improved significantly
2 for ischemic patients and in tertiary hospitals while for hemorrhagic patients and
3 in non-tertiary hospitals only the health-related quality of life improved
4 significantly.

5 · This is the first study to compare the costs and effects of implementing a nursing
6 intervention program on immobile stroke patients, providing a realistic picture of
7 the health benefits that could be achieved if this program were implemented on a
8 nationwide scale.

9 **Key words:** Cost-effectiveness; Cost-utility analysis; Costs and cost analysis; Nursing;
10 Stroke; Health-related quality of life; Propensity score; Predictive mean matching;
11 Multicenter study

1. Introduction

Stroke is the second leading cause of death and disability worldwide (Hankey, 2017, Wu et al., 2019), levying high annual costs on hospitals, the health system and the society (Kim et al., 2015). It is estimated that €64.1 billion is spent yearly on stroke in Europe (Feigin et al., 2015), of which about two-thirds is for direct stroke health care costs (Feigin et al., 2015). Accounting for about one-third of global deaths from stroke (Feigin et al., 2015), China's 2.5 million annual new strokes victims and 7.5 million stroke survivors (Johnston et al., 2009, Liu et al., 2011), impose significant costs on China's health system. Stroke survivors are frequently made immobile, suffering medical complications (Kumar et al., 2010) such as pressure injuries (McGillivray and Considine, 2009, Pandian et al., 2012, Sackley et al., 2008, Theofanidis and Gibbon, 2016), pneumonia (Kumar et al., 2010, McGillivray and Considine, 2009, Sidhartha et al., 2015), deep vein thrombosis (Kumar et al., 2010, Shah et al., 2015, Sidhartha et al., 2015) and urinary tract infections (Pandian et al., 2012, Sidhartha et al., 2015, Yan et al., 2018). These stroke-related complications may severely hinder the functional recovery of stroke patients, resulting in poorer final recovery outcomes, increasing the length of hospital stays and decreasing patient's quality of life (Kumar et al., 2010). They impose significant costs on China's health care system.

Previous studies indicate that complications after stroke can increase the costs of health care and account for a significant part of direct costs of stroke (Demaerschalk et al., 2010, Joo et al., 2014, Kumar et al., 2010, Navarrete-Navarro et al., 2007, Sackley et al., 2008). In 2017 for example, the cost per hospitalization for ischemic stroke was

1 CN¥10,131, while China's per capita disposable income was CN¥25,974 (Yong et al.,
2 2018). Currently, the direct costs for stroke treatment in China is about CN¥37.5 billion
3 annually, or CN¥50 billion when indirect costs are included (Wu et al., 2015). For
4 patients immobilized by stroke, the cost of stroke care due to medical complications
5 may increase the economic burden of stroke (Liu et al., 2011, Westendorp et al., 2018).

6 But, with timely assessment and standardized nursing care, such as general body
7 support, physiological surveillance and early mobilization, many of these complications
8 are preventable or the adverse outcomes ameliorated (Bae et al., 2005, Johnston et al.,
9 1998, Langhorne et al., 2000, McGillivray and Considine, 2009). Some randomized
10 controlled trials (RCTs) have shown that standardized and integrated nursing care may
11 lead to better outcomes in the acute phase of stroke care (Indredavik et al., 2000, Sinha
12 and Warburton, 2000, Sulch et al., 2002) and several investigators have shown that
13 standardized nursing interventions can reduce the frequency of stroke complications,
14 decrease stroke health care costs and improve the health-related quality of life of
15 immobile stroke patients (Anthony, 2013, Balami et al., 2011, Granitto and Galitz, 2008,
16 Lombard et al., 2009, Miller, 2016, Quinn et al., 2014).

17 Surprisingly, few cost-effectiveness analyses of nursing interventions for
18 immobile stroke patients have been undertaken in China. Supported by National Health
19 and Family Planning Commission's agenda to improve the quality of nursing care and
20 clinical outcomes among immobile patients, our study developed a standardized
21 nursing intervention program for immobile patients with four major immobility
22 complications: pressure injuries, deep vein thrombosis, pneumonia and urinary tract

infections. Training in our intervention program was conducted in 25 hospitals from six provinces or municipal cities in China (Eastern: Guangdong province, Zhejiang province, Beijing municipal city; Western: Sichuan province; and Central China: Henan province and Hubei province), comprising six tertiary hospitals, 11 secondary hospitals and eight community hospitals.

Our previously study found that compared with routine nursing care, the intervention program decreased the incidences of major immobility complications and improved clinical outcomes in immobile patients (Liu et al., 2019, Wu et al., 2018), but did not evaluate the cost-effectiveness of routine versus intervention care. Taking a health care perspective, we used the propensity score matching statistical technique and cost-utility analysis to investigate whether implementing an intervention program can both improve the health-related quality of life and save health care costs for immobile stroke patients. Specifically, we test whether hemorrhagic and ischemic stroke might be prone to different complications (Ali et al., 2009, Bae et al., 2005, Dennis et al., 2016, Kong et al., 2016, Kumar et al., 2010, Liu et al., 2018) with different health care cost effectiveness implications. We also test whether there were significant differences in nursing care costs effectiveness between tertiary and non-tertiary hospitals (Liu et al., 2019).

2. Methods

2.1. Study design and participants

Our study design is a pre-test/post-test (before and after) study, comparing immobile patients with ischemic and hemorrhagic stroke in the intervention group versus routine

1 care group from 25 hospitals in China between November 2015 and July 2017. For the
2 routine care group, 3,891 patients were recruited from November 2015 to June 2016,
3 and for the intervention group, 3,762 patients were recruitment from November 2016
4 to July 2017. All patients were followed-up 3 months after enrolment in the study.

5 Between November 2015 and June 2016, we developed the intervention program
6 based on baseline data (such as the frequency of complications in immobile stroke
7 patients, nursing interventions being implemented for stroke and complications),
8 evidence-based results, and expert opinions. The intervention program contains
9 enhanced nursing practices that reflect specific knowledge and skills, such as risk
10 factors assessment, observation, nursing precaution, nursing intervention, and nursing
11 operations. Details of the intervention program design, the characteristics, training
12 information, and process of data collection are describe in the Supplemental On-line
13 Information).

14 At 25 hospitals, data on all immobile patients suffering ischemic and hemorrhagic
15 stroke between November 2015 and July 2017 were analyzed. Inclusion criteria
16 comprised being immobile, for at least 24 hours after admission, defined as patients'
17 basic physiological needs being carried out in bed except for active or passive bedside
18 sitting/standing/wheelchair use for examination; granting informed consent; older than
19 18 years; and diagnosed with ischemic or hemorrhagic stroke. Exclusion criterion was
20 patients with major immobility complication at the time of enrolment.

21 Using an individual case report form (CRF) from time of enrolment, two pre-
22 trained registered nurses in each ward collected data on patients' socio-demographic

1 characteristics (age, sex, education level, health behavior, insurance type, and region),
2 frequency of major immobility complications and nursing interventions implemented
3 for stroke and major immobility complications. Data collected by nurses were checked
4 daily by the head nurse, including for missing data, to provide validity checks. Costs
5 were derived from the hospital information system (HIS) in each hospital after the
6 enrolled patients were discharged from the hospital, and their health-related quality of
7 life information was gathered 3 months after enrollment using the three-level EuroQol
8 five-dimensional questionnaire (EQ-5D), a standardized instrument for measuring
9 health status, through telephone follow-ups (Golicki et al., 2015), unless they died in
10 hospital or withdrew from medical treatment.

11 In the final analysis, 7,653 patients were included in our sample. There were 378
12 (4.94%) patients who died; 575 (7.51%) patients withdrew from treatment; and 224
13 (2.93%) patients were missing hospital cost data. The study was ethically approved by
14 the authorities of the 25 cooperating hospitals and participants signed a written
15 informed consent before enrolment. For patients with aphasia to consent, consent was
16 signed by a family member.

17 *2.2. Costs and Utility Values*

18 The economic evaluation was conducted from a health care perspective with a 3 month
19 time horizon, meaning that only direct costs within the health care sector were included,
20 and were discounted at a rate of 3% per annum (Ma et al., 2015, Wang et al., 2019,
21 Yang et al., 2012). The China Health Statistics Yearbook indicated that the price index
22 was 2.7 in 2015, and the price index was 3.5 in 2016, the average of the two years of

1 the price index is 3.1, therefore, it was reasonable to choose a discount rate of 3% in
2 the present study. Widely used in economic evaluations of stroke disease (Hunter et al.,
3 2018, Westendorp et al., 2018), cost-effective analysis, a variant of cost-utility analysis,
4 combines the incremental utilities expressed in the unit of quality-adjusted life years
5 (QALYs) gained by a certain intervention with the costs produced by that intervention
6 (Angevine and Berven, 2014). Effectiveness of the intervention program was measured
7 by the EQ-5D index, a standardized instrument for measuring generic health status,
8 comprising five dimensions: mobility, self-care, usual activities, pain/discomfort and
9 anxiety/depression on a three-point scale (no/some/extreme problems). EQ-5D
10 generates preference-based scores for health-related quality of life that was used to
11 calculate quality-adjusted life years (Golicki et al., 2015). A literature review revealed
12 that the EQ-5D appears to be appropriately responsive in stroke patients (Golicki et al.,
13 2015), therefore, we considered the progression of EQ-5D scores during the 3-month
14 follow-up period. EQ-5D responses were then valued using population preferences in
15 China (Liu et al., 2014). Cost-effectiveness was measured using the incremental cost-
16 effectiveness ratio (ICER), which is the ratio of the difference in mean cost between
17 intervention group and the routine care group and the difference in their mean effect
18 (Postmus et al., 2011). In cost-utility analysis, it represents the average incremental cost
19 associated with per quality-adjusted life year gained. If the incremental cost per
20 effectiveness is less than 0, the intervention can save costs while achieving health
21 benefit, and if it is less than gross domestic product (GDP) per capita, the intervention
22 can be regarded as highly cost-effective, and it can be regarded as cost-effective if the

1 incremental cost-effectiveness ratio is not more than 3 times the GDP per capita (Wang
2 et al., 2019, Who, 2001, Yang et al., 2012). This approach has already been used in
3 several economic evaluations in many developing countries, including China (Ma et al.,
4 2015, Rachapelle et al., 2013, Xie and Vondeling, 2008, Yang et al., 2012).The GDP
5 per capita for China in 2016 was CN¥53,980; we used CN¥53,980 per quality-adjusted
6 life year as the threshold ratio of willingness to pay (WTP) to determine whether the
7 interventions were cost-effective or not.

8 *2.3. Statistical analysis*

9 To adjust for potential bias from confounding variables, we match the two groups of
10 patients according to their characteristics and facility characteristics. Patients in the
11 routine care group were matched 1:1 to patients in the intervention group by the
12 propensity score using the greedy matching algorithm. We derived the propensity score
13 from a logistic regression model with the following variables: age, sex, education level,
14 smoking, insurance, region, level of hospital, bed time, experience of intensive care unit
15 (ICU), experience of surgery, respiratory invasive operation within one month,
16 tracheotomy within one month, urethral invasive operation within one month and
17 number of Charlson comorbidities (Bar and Hemphill, 2011). Region and level of
18 hospital refer to the provider/facility characteristics in the present study. When all
19 propensity score matches were performed, we assessed the balance in baseline
20 covariates between the two groups using the χ^2 test.

21 Sample exclusion due to missing values may be sources of bias, if the missing
22 values are not random. To address this concern, we investigated whether the missing

1 sample are different from those non-missing data (see Supplementary Table 2). We
2 found significant differences in some variables between those with and without data.
3 Therefore, to reduce the potential bias of missing data, we replaced missing values for
4 cost and effect data with 10 imputed values using multiple imputation by chained
5 equations (MICE) with predictive mean matching (PMM) (Faria et al., 2014, White et
6 al., 2011). Then we used a mixed effects model to allow for the correlation between
7 measurements over hospitals; a log link function with a gamma distribution for the costs;
8 and an identity function with a Gaussian distribution for health-related quality of life.

9 *2.4. Uncertainty*

10 We created 5,000 bootstrapped replications by drawing 500 samples of the same size
11 as the original samples with replacement from each of the 10 imputations to compute
12 5,000 bootstrap replication of the cost-effectiveness ratio and then plotted the
13 corresponding cost-effectiveness plane and cost effectiveness acceptability curves
14 (Fenwick et al., 2004, Westendorp et al., 2018). The cost-effectiveness plane shows
15 differences in costs in the Y-axis and differences in effect on the X-axis. Results of
16 bootstrapping are reported with quadrants of the differences in costs against the
17 differences in effectiveness. The cost effectiveness acceptability curves shows the
18 probability of interventions being more efficient than routine care for different levels
19 of willingness to pay per unit decrease per additional quality-adjusted life year
20 (Fenwick et al., 2004, Westendorp et al., 2018). The cost effectiveness acceptability
21 curves are derived from the joint density of incremental costs and incremental effects
22 and represents the proportion of the density where the intervention is cost-effective for

1 a range of values of willingness to pay. We estimated cost effectiveness acceptability
2 curves via the distribution from the 5,000 bootstrapped replications. The cost
3 effectiveness acceptability curve is determined as the proportion of the incremental
4 cost-effectiveness ratio points where the intervention is cost-effective (Fenwick et al.,
5 2004, Lothgren and Zethraeus, 2000, van Hout et al., 1994).

6 To explore whether the intervention program is more likely to be cost-effective for
7 patients with varying pathological subtypes and hospital level, we computed separate
8 incremental cost-effectiveness ratio and acceptability curves with varying pathological
9 subtypes and hospital levels.

10 *2.5. Sensitivity Analysis*

11 We investigated the influence of imputing missing survey data on the results by
12 reporting the incremental cost-effectiveness ratio for the observed data only (available
13 non-missing data analysis). ~~Only observed data without missing values were included.~~

14 To investigate the potential influence of the propensity score matching techniques on
15 the results, we replaced one-to-one matching by Mahalanobis distance matching. In this
16 analysis, all cases were included and Mahalanobis distance matching was performed in
17 each of the 5,000 bootstrapped samples before estimating the incremental cost-
18 effectiveness ratio.

19 We conducted all analyses in Stata version 15 for Windows (Stata Corp, College
20 Station, TX, USA).

21 **3. Results**

22 *3.1. Baseline characteristics in both original and matched cohorts*

1 Table 1 summarizes patient clinical characteristics and baseline demographics. In the
2 original cohort (before propensity score matches were performed), there were significant
3 differences between the routine care group and the intervention group in sex, education,
4 smoking, bedtime, number of Charlson comorbidities, levels of hospital and province.
5 Experience with ICU, urethral invasive operation and tracheotomy within one month
6 were significantly higher in the intervention group compared to the routine care group.
7 There were no significant differences in age, insurance, experience of surgery and
8 respiratory invasive operation within one month between the two groups. The average
9 direct medical costs per patient in the routine care group was CN¥50,996, and the
10 quality-adjusted life year was 0.175. The average direct medical costs per patient in the
11 intervention group was CN¥48,641, and the quality-adjusted life year was 0.178.

12 In the matched data, the 1:1 propensity score matching yielded matched pairs of
13 2,966 patients in the routine care group and 2,966 patients in the intervention group,
14 with no significant differences in sociodemographic or clinical characteristics between
15 two groups. The average direct medical costs per patient in the routine care group was
16 CN¥51,244, and the quality-adjusted life year in 3 months was 0.172. The average
17 direct medical costs per patient in the intervention group was CN¥46,740, and the
18 quality-adjusted life year in 3 months was 0.182.

19 *3.2. Total costs, quality-adjusted life year gained, and incremental cost-effectiveness*
20 *ratio of intervention group compared with routine care group in the matched cohorts*

21 As shown in Table 2, based on the matched cohorts with imputed data, the average
22 direct medical costs per patient in the routine care group was CN¥51,610, while it was

1 CN¥46,921 in the intervention group, and the health-related quality of life in 3 months
2 for patients in the routine care group was 0.170 while it was 0.179 in the intervention
3 group. After the program implementation, the total costs decreased CN¥4,689 (95%
4 confidence interval [CI]: [-7815, -1562]), and the quality-adjusted life year in 3
5 months increased 0.010 (95% CI: [0.005, 0.014]), which resulted in an incremental
6 cost-effectiveness ratio of CN¥ -480,077 per quality-adjusted life year (95% CI: [-
7 1065860, -141378). ~~However,~~ After adjusting for baseline covariates using the mixed
8 effects model, the total costs decreased CN¥4,600 (95% CI: [-7050, -2151]), and the
9 quality-adjusted life year in 3 months increased 0.009 (95% CI: [0.005, 0.013]), with
10 the incremental cost-effectiveness ratio decreasing significantly to CN¥-517,011 per
11 quality-adjusted life year.

12 3.3. Uncertainty analysis

13 In Figure 1, the cost-effectiveness plane and the cost-acceptability curve are shown
14 based on 5,000 bootstrapped replications. As can be seen, 99.6% of incremental cost-
15 effectiveness ratios fell into the south-east quadrant, indicating that the intervention
16 program generated greater quality-adjusted life years and was less expensive compared
17 to routine care. At an incremental cost-effectiveness ratio of CN¥53,980 (GDP per
18 capita for China in 2016) per quality-adjusted life year, there is a 99.8% probability that
19 the intervention program is cost-effective, and at an incremental cost-effectiveness ratio
20 of CN¥ 85,926 per quality-adjusted life year, there is 100% probability that the
21 intervention program was cost-effective.

22 Table 3 displays subgroup analysis according to pathological subtypes and hospital

1 levels. For ischemic stroke patients, total costs decreased CN¥5,402 (41,105 to 35,516,
 2 95% CI:[-8508,-2296]) and quality-adjusted life year in 3 months increased 0.011
 3 (0.167 to 0.179, 95% CI:[0.006, 0.016]), which resulted in an incremental cost-
 4 effectiveness ratio of CN¥-534,488 per quality-adjusted life year (95% CI:[-1102479,
 5 -210430]). In hemorrhagic stroke patients, total costs decreased CN¥3,328 (72,274 to
 6 69,717, 95% CI:[-7068, 412]), and the quality-adjusted life year in 3 months increased
 7 0.008 (0.176 to 0.181, 95% CI:[0.001, 0.015]), which resulted in an incremental cost-
 8 effectiveness ratio of CN¥-944,350 per quality-adjusted life year (95% CI:[-3922489,
 9 88597]). In tertiary hospitals, the total costs decreased CN¥9,690 (67,430 to 60,605, 95%
 10 CI:[-13259, -6120]) and the quality-adjusted life year in 3 months increased 0.008
 11 (0.171 to 0.180, 95% CI:[0.003, 0.013]), which resulted in an incremental cost-
 12 effectiveness ratio of CN¥ -1,377,239 per quality-adjusted life year in 3 months (95%
 13 CI:[-2987794, -648137]). Total costs increased CN¥31 in non-tertiary hospitals, but
 14 decreased CN¥1,446 (16,270 to 16,301, 95% CI:[-4396,1463]) after adjusting for
 15 baseline covariates using the mixed effects model, with the quality-adjusted life year in
 16 3 months increasing 0.015 (0.167 to 0.178, 95% CI:[0.008,0.022]), which resulted in
 17 an incremental cost-effectiveness ratio of CN¥-101,729 per quality-adjusted life year
 18 (95% CI:[-346392, 107194]).

19 After bootstrapping based on the imputed data, the incremental cost-effectiveness
 20 ratios were again plotted on a cost-effectiveness plane and a cost-acceptability curve
 21 plotted in Figure 2. For hemorrhagic stroke patients, 71.14% of the ratios fell into the
 22 south-east quadrant and 17.49% fell into the north-east quadrant. At a threshold of

1 CN¥ 53,980 per quality-adjusted life year, there is 81.1% probability that the
2 intervention program was cost-effective. At an incremental cost-effectiveness ratio of
3 CN¥ 161,940 (3 times the GDP per capita for China in 2016) per quality-adjusted life
4 year, the probability that the intervention program was more cost effective than routine
5 care was about 84%. For ischemic stroke patients, 100% of the incremental cost-
6 effectiveness ratios fell into the south-east quadrant, indicating that the intervention
7 program generated greater utilities and was less expensive than routine care. In tertiary
8 hospitals, 99.96% of the ratios fell into the south-east quadrant, indicating that the
9 intervention program generated greater utilities and was less expensive compared to
10 routine care. In non-tertiary hospitals, 50.12% of the incremental cost-effectiveness
11 ratios fell into the north-east and 49.28% fell in the south-east quadrant. At a threshold
12 of CN¥ 53,980 per quality-adjusted life year, there was a 68.7% probability that the
13 intervention program was cost-effective. At an incremental cost-effectiveness ratio of
14 CN¥ 161,940 per quality-adjusted life year, the intervention program had a probability
15 of 89.6% of being optimal against routine care.

16 3.4 *Sensitivity analysis*

17 Table 4 depicts the influence of imputing missing data on the results by reporting
18 the incremental cost-effectiveness ratio for the observed data only (available non-
19 missing data analysis). In this analysis, only observed data without missing values were
20 included, and we found consistent results across these two data sets. Employing the
21 Mahalanobis distance matching in Table 4, we also investigated the potential influence
22 of the propensity score matching techniques on the results by reporting the incremental

1 cost-effectiveness ratio (ICER). We found consistent results by these two matching
2 techniques.

3 **4. Discussion**

4 Researchers from different countries recommend that stroke care can tackle the stroke
5 cost burden (Grieve et al., 2000, The, 2019, van Exel et al., 2005). We developed the
6 standardized nursing intervention program based on evidence-based nursing practice.
7 Nurses were trained in the intervention program, then the intervention program was
8 applied to immobile stroke patients, which showed that integrated nursing care could
9 significantly lower immobile stroke patient costs and improve the health care of stroke
10 patients. After adjusted for baseline covariates using the mixed effects model, the result
11 indicates that a nurse-led intervention program for immobile stroke patients decreased
12 stroke care costs by CN¥4,600 after adjustment for baseline covariates and increased
13 the quality-adjusted life year in 3 months at 0.009. The intervention program led to a
14 significant improvement in general health status for immobile stroke patients in an
15 unequivocally cost-efficient way, which improved the health-related quality of life at
16 an expected cost saving to health care system of CN¥517,011. A previously study
17 showed that compared to routine nursing care, an intervention program can decrease
18 the incidences of major immobility complications and improved clinical outcomes for
19 immobile patients (Liu et al., 2019). While achieving improved health outcomes, this
20 paper shows that implementing a nurse-led intervention program can also save costs.

21 To our knowledge, this is the largest multicenter study of a nursing program for
22 immobile stroke patients and the first report on the economic evaluation of an

1 intervention program conducted in China. After the application of the intervention
2 program, the quality-adjusted life year improved +0.01 in 3 months, which is similar to
3 the results of an American nurse-led disease management program for heart failure
4 (Hebert et al., 2008). Research from the Netherlands indicated that the incremental cost-
5 effectiveness ratio of their integrated stroke services in Delft was €19,350 less per
6 quality-adjusted life year gained (van Exel et al., 2005), and a stroke care model from
7 Copenhagen suggested that the incremental cost-effectiveness ratio was US\$21,579 per
8 quality-adjusted life year gained for continent patients and US\$37,444 for incontinent
9 patients (Grieve et al., 2000). The incremental cost-effectiveness ratios from these
10 studies were much higher than the incremental cost-effectiveness ratio of our China
11 intervention program. Part of the reason is that the Dutch and Swedish stroke care
12 models were more structured than our intervention program. Our program contains
13 major immobility complications standardized nursing care interventions and skills
14 required by nurses working in hospital stroke facilities, while the integrated stroke
15 services in the Netherlands contained one hospital stroke unit, one nursing home stroke
16 unit, one rehabilitation center and one home care provider, all supported by a stroke
17 nurse (van Exel et al., 2005), thus the resources and costs included in their model may
18 lead to incremental cost-effectiveness ratios somewhat higher than the incremental cost-
19 effectiveness ratios for our program. Although the stroke care models in different
20 countries may vary between countries, generally, these integrated stroke nursing
21 measures were cost-efficient. Therefore, our results confirm evidence that, compared
22 with routine stroke nursing care, improved standardized nursing interventions can save

1 costs and are also more effective in health-related quality of life outcomes than routine
2 care.

3 In ischemic stroke patients, 100% of the ratios fall into the south-east (less cost
4 and high quality-adjusted life years) quadrant, indicating that the intervention program
5 saved costs while achieving health outcome benefits for patients. While in hemorrhagic
6 stroke patients, at a threshold of CN¥ 53,980 per quality-adjusted life year, there was
7 an 81.1% probability that the intervention was cost-effective, and at an incremental
8 cost-effectiveness ratio of CN¥ 161,940 (3 times the GDP per capita for China in 2016)
9 per quality-adjusted life year, there was an 84.0% probability that the intervention was
10 cost-effective. Although the health-related quality of life improved significantly in both
11 ischemic and hemorrhagic stroke patients, the cost did not decrease significantly in
12 patients with hemorrhagic stroke, but did decrease significantly for ischemic stroke
13 patients. Compare with hemorrhagic stroke patients, deep vein thrombosis and
14 pneumonia are frequent complications in ischemic stroke, which significantly
15 contribute to hospital cost (Ali et al., 2009, Dennis et al., 2016, Kong et al., 2016).
16 Through implementing the intervention program, ischemic stroke patients may reduce
17 hospital costs due to pneumonia and deep vein thrombosis, but not for hemorrhagic
18 stroke patients that had a much lower incidence of pneumonia and deep vein thrombosis.

19 In tertiary hospitals, 99.96% of the ratios fall into the south-east (less cost and high
20 quality-adjusted life years) quadrant, indicating that the intervention program generates
21 greater utilities and is less expensive compared to routine care. In non-tertiary hospitals,
22 there was a 68.7% probability that the intervention is cost-effective at a threshold of

1 CN¥ 53,980 per quality-adjusted life year. The quality-adjusted life year improved in
2 non-tertiary hospitals was much more than the tertiary hospitals (0.015 versus 0.008),
3 while there was no significant reduction in total costs in non-tertiary hospitals compare
4 with the tertiary hospitals (-1466 versus -9690). The potential reasons for this difference
5 may be the disparities in major immobility complications related nursing care (Xiaojing
6 et al., 2016). Before the intervention program implementation, nursing care were less
7 standardization in non-tertiary hospitals compared to tertiary hospitals. The
8 intervention program training will significantly improve standards of care in non-
9 tertiary hospitals, but increase the costs related to nursing care, offsetting the reduction
10 of the costs due to major immobility complications, which may explain the insignificant
11 improvement in total cost. Further, the intervention program's large improvement in
12 nursing care will lead to large improvements in non-tertiary hospitals' quality-adjusted
13 life year.

14 Our study has several potential limitations. First, we conducted a historical and
15 comparative study and the routine care group and intervention group were not
16 conducted at the same time, so there may be potential bias due to changes in the
17 treatment trends during the study periods. Mediating this concern is that the gap
18 between these periods was only 1 year. Also the quality control system was applied to
19 the patients in each hospital (Liu et al., 2019), with a structured, systematic nursing
20 intervention model implemented for each patient, so the patients in this study
21 experienced homogeneous care. Second, we only had a limited 3 month follow up,
22 which means future research should conduct a long-term follow-up study of the health-

1 related quality of life. Third, we did not calculate the indirect and intangible costs of
2 the intervention program, which means that the effectiveness of this program was
3 probably underestimated.

4 A strong point of our study is that the analysis was based on individual patient data
5 collected at 25 hospitals across China. This is the first study to compare the costs and
6 effects of implementing an intervention program on immobile stroke patients, providing
7 a realistic picture of the health benefits that could be achieved if the program were
8 implemented on a nationwide scale. Previous studies on the cost effectiveness of nurse-
9 led disease or illness complications management programs were conducted in single
10 hospital (Avşar and Karadağ, 2018, Gallefoss, 2004), thus lacking generalizability. We
11 applied propensity score matching to reduce any potential biases between the two
12 groups. We found that there was no significant difference between the two groups after
13 matching, which indicates the propensity score matching improved the reliability of our
14 results. We also replaced missing values data with 10 imputed values, using multiple
15 imputation by chained equations. Finally, the sensitivity analyses suggest that the
16 results are robust across different matching techniques and data sets.

17 Our results provide useful information for decision makers who draft policy for
18 health insurance services. One recommendation is for insurance policies to re-
19 customize the proportion of reimbursement for immobile stroke patients for different
20 pathological subtypes and levels of hospitals. We also recommend developing clinical
21 nursing practice care bundles for subtypes of strokes as well as other illnesses (Lavallée
22 et al., 2017, Wunderink and Waterer, 2017), which will improve patients' health-related

1 quality of life, attenuate the incidence of major immobility complications and save
2 hospital costs. Policymakers should construct support networks for non-tertiary
3 hospitals to help them improve their knowledge, attitudes and standards of nursing care.
4 In addition, with population aging and an ongoing high prevalence of risk factors, such
5 as hypertension, obesity and diabetes, in the population, the development and
6 implementation of similar nursing care intervention programs should be a priority in
7 the "Healthy China 2030" Planning Outline. Finally, China should promote integrated
8 stroke services, which include hospital stroke units, nursing home stroke units,
9 rehabilitation centers, home-visit nursing utilization and home-visit nurses (Grieve et
10 al., 2000).

11 **5. Conclusions**

12 At less than CN¥517,011 per quality-adjusted life year saved, our nurse-led
13 intervention program was cost-effective over 3 months, especially for ischemic stroke
14 patients and tertiary hospitals. In terms of cost-effectiveness, this program was
15 particularly promising for immobile patients with stroke who receive nursing care in a
16 hospital setting. Our findings suggest improved health outcomes for the intervention
17 group patients and cost-effectiveness for hospitals. The wider adoption of such nursing
18 interventions programs may be a sensible approach to reducing the burden of stroke in
19 non-tertiary hospitals and for immobile patients suffering non-stroke illnesses.

20 **Acknowledgements**

21 The authors are indebted to all participants of this study. We are grateful to the nursing
22 staff at each hospital site who were instrumental for the successful implementation of

1 this project. We acknowledge the helpful comments by two anonymous reviewers.

2 **Conflict of interest**

3 We declare no competing interests relevant to this manuscript.

4 **Funding**

5 This paper was supported by the National Health and Family Planning Commission
6 (Beijing, China) [grant numbers 201502017].

7 **Authors' contributions**

8 XW conceived and designed this study and reviewed the manuscript, HL prepared and
9 edited the manuscript. DZ performed statistical analyses and drafted the tables. BS, JJ,
10 YL, XW, SC, and SN recruited participants, collected data, and edited the manuscript.

11 **References**

- 12 Ali, M., Sacco, R.L., Lees, K.R., 2009. Primary end-point times, functional outcome and adverse event
13 profile after acute ischaemic stroke. *Int J Stroke* 4 (6), 432-442.
- 14 Angevine, P.D., Berven, S., 2014. Health economic studies: an introduction to cost-benefit, cost-
15 effectiveness, and cost-utility analyses. *Spine* 39 (22 Suppl 1), S9-15.
- 16 Anthony, M., 2013. Nursing assessment of deep vein thrombosis. *Medsurg Nurs* 22 (2), 95-98, 123.
- 17 Avşar, P., Karadağ, A., 2018. Efficacy and Cost-Effectiveness Analysis of Evidence-Based Nursing
18 Interventions to Maintain Tissue Integrity to Prevent Pressure Ulcers and Incontinence-
19 Associated Dermatitis. *Worldviews Evid Based Nurs* 15 (1), 54-61.
- 20 Bae, H.J., Yoon, D.S., Lee, J., Kim, B.K., Koo, J.S., Kwon, O., Park, J.M., 2005. In-hospital medical
21 complications and long-term mortality after ischemic stroke. *Stroke* 36 (11), 2441-2445.
- 22 Balami, J.S., Chen, R.L., Grunwald, I.Q., Buchan, A.M., 2011. Neurological complications of acute
23 ischaemic stroke. *Lancet Neurol* 10 (4), 357-371.
- 24 Bar, B., Hemphill, J.C., 3rd, 2011. Charlson comorbidity index adjustment in intracerebral hemorrhage.
25 *Stroke* 42 (10), 2944-2946.
- 26 Demaerschalk, B.M., Hwang, H.M., Leung, G., 2010. US cost burden of ischemic stroke: a systematic
27 literature review. *Am J Manag Care* 16 (7), 525-533.
- 28 Dennis, M., Caso, V., Kappelle, L.J., Pavlovic, A., Sandercock, P., 2016. European Stroke Organisation
29 (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute
30 ischaemic stroke. *Eur Stroke J* 1 (1), 6-19.
- 31 Faria, R., Gomes, M., Epstein, D., White, I.R., 2014. A guide to handling missing data in cost-
32 effectiveness analysis conducted within randomised controlled trials. *Pharmacoeconomics* 32

1 (12), 1157-1170.

2 Feigin, V.L., Krishnamurthi, R.V., Parmar, P., Norrving, B., Mensah, G.A., Bennett, D.A., Barker-Collo,
3 S., Moran, A.E., Sacco, R.L., Truelsen, T., Davis, S., Pandian, J.D., Naghavi, M., Forouzanfar,
4 M.H., Nguyen, G., Johnson, C.O., Vos, T., Meretoja, A., Murray, C.J., Roth, G.A., 2015. Update
5 on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study.
6 *Neuroepidemiology* 45 (3), 161-176.

7 Feigin, V.L., Mensah, G.A., Norrving, B., Murray, C.J., Roth, G.A., 2015. Atlas of the Global Burden of
8 Stroke (1990-2013): The GBD 2013 Study. *Neuroepidemiology* 45 (3), 230-236.

9 Fenwick, E., O'Brien, B.J., Briggs, A., 2004. Cost-effectiveness acceptability curves--facts, fallacies and
10 frequently asked questions. *Health Econ* 13 (5), 405-415.

11 Gallefoss, F., 2004. The effects of patient education in COPD in a 1-year follow-up randomised,
12 controlled trial. *Patient Educ Couns* 52 (3), 259-266.

13 Golicki, D., Niewada, M., Karlinska, A., Buczek, J., Kobayashi, A., Janssen, M.F., Pickard, A.S., 2015.
14 Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. *Qual*
15 *Life Res* 24 (6), 1555-1563.

16 Granitto, M., Galitz, D., 2008. Update on stroke: the latest guidelines. *Nurse Pract* 33 (1), 39-46; quiz 47.

17 Grieve, R., Porsdal, V., Hutton, J., Wolfe, C., 2000. A comparison of the cost-effectiveness of stroke care
18 provided in London and Copenhagen. *Int J Technol Assess Health Care* 16 (2), 684-695.

19 Hankey, G.J., 2017. Stroke. *Lancet* 389 (10069), 641-654.

20 Hebert, P.L., Sisk, J.E., Wang, J.J., Tuzzio, L., Casabianca, J.M., Chassin, M.R., Horowitz, C.,
21 McLaughlin, M.A., 2008. Cost-effectiveness of nurse-led disease management for heart failure
22 in an ethnically diverse urban community. *Ann Intern Med* 149 (8), 540-548.

23 Hunter, R.M., Fulop, N.J., Boaden, R.J., McKevitt, C., Perry, C., Ramsay, A.I.G., Rudd, A.G., Turner,
24 S.J., Tyrrell, P.J., Wolfe, C.D.A., Morris, S., 2018. The potential role of cost-utility analysis in
25 the decision to implement major system change in acute stroke services in metropolitan areas
26 in England. *Health Res Policy Syst* 16 (1), 23.

27 Indredavik, B., Fjaertoft, H., Ekeberg, G., Loge, A.D., Mørch, B., 2000. Benefit of an extended stroke
28 unit service with early supported discharge: A randomized, controlled trial. *Stroke* 31 (12),
29 2989-2994.

30 Johnston, K.C., Li, J.Y., Lyden, P.D., Hanson, S.K., Feasby, T.E., Adams, R.J., Faught, R.E., Jr., Haley,
31 E.C., Jr., 1998. Medical and neurological complications of ischemic stroke: experience from the
32 RANTTAS trial. RANTTAS Investigators. *Stroke* 29 (2), 447-453.

33 Johnston, S.C., Mendis, S., Mathers, C.D., 2009. Global variation in stroke burden and mortality:
34 estimates from monitoring, surveillance, and modelling. *Lancet Neurol* 8 (4), 345-354.

35 Joo, H., George, M.G., Fang, J., Wang, G., 2014. A literature review of indirect costs associated with
36 stroke. *J Stroke Cerebrovasc Dis* 23 (7), 1753-1763.

37 Kim, A.S., Cahill, E., Cheng, N.T., 2015. Global Stroke Belt: Geographic Variation in Stroke Burden
38 Worldwide. *Stroke* 46 (12), 3564-3570.

39 Kong, X.L., Zhang, X., Zhang, S.J., Zhang, L., 2016. Plasma Level of D-dimer is an Independent
40 Diagnostic Biomarker for Deep Venous Thrombosis in Patients with Ischemic Stroke. *Curr*
41 *Neurovasc Res* 13 (2), 100-106.

42 Kumar, S., Selim, M.H., Caplan, L.R., 2010. Medical complications after stroke. *Lancet Neurol* 9 (1),
43 105-118.

44 Langhorne, P., Stott, D.J., Robertson, L., MacDonald, J., Jones, L., McAlpine, C., Dick, F., Taylor, G.S.,

- 1 Murray, G., 2000. Medical complications after stroke: a multicenter study. *Stroke* 31 (6), 1223-
2 1229.
- 3 Lavallée, J.F., Gray, T.A., Dumville, J., Russell, W., Cullum, N., 2017. The effects of care bundles on
4 patient outcomes: a systematic review and meta-analysis. *Implement Sci* 12 (1), 142.
- 5 Liu, G.G., Wu, H., Li, M., Gao, C., Luo, N., 2014. Chinese time trade-off values for EQ-5D health states.
6 *Value Health* 17 (5), 597-604.
- 7 Liu, H., Zhu, D., Cao, J., Jiao, J., Song, B., Jin, J., Liu, Y., Wen, X., Cheng, S., Nicholas, S., Wu, X.,
8 2019. The effects of a standardized nursing intervention model on immobile patients with stroke:
9 a multicenter study in China. *European journal of cardiovascular nursing : journal of the*
10 *Working Group on Cardiovascular Nursing of the European Society of Cardiology* 18 (8), 753-
11 763.
- 12 Liu, L., Wang, D., Wong, K.S., Wang, Y., 2011. Stroke and stroke care in China: huge burden, significant
13 workload, and a national priority. *Stroke* 42 (12), 3651-3654.
- 14 Liu, X., Kong, D., Lian, H., Zhao, X., Zhao, Y., Xu, Q., Peng, B., Wang, H., Fang, Q., Zhang, S., Jin, X.,
15 Cheng, K., Fan, Z., 2018. Distribution and predictors of hospital charges for haemorrhagic
16 stroke patients in Beijing, China, March 2012 to February 2015: a retrospective study. *BMJ*
17 *Open* 8 (3), e017693.
- 18 Lombard, L.A., Reddy, C.C., Moroz, A., Lew, H.L., Chae, J., Edgley, S.R., 2009. Stroke and
19 Neurodegenerative Disorders: 2. Poststroke Medical Complications. *PM&R* 1 (3), S13-S18.
- 20 Lothgren, M., Zethraeus, N., 2000. Definition, interpretation and calculation of cost-effectiveness
21 acceptability curves. *Health Econ* 9 (7), 623-630.
- 22 Ma, Y., Ying, X., Zou, H., Xu, X., Liu, H., Bai, L., Xu, X., Zhang, X., 2015. Cost-utility analysis of
23 rhegmatogenous retinal detachment surgery in Shanghai, China. *Ophthalmic Epidemiol* 22 (1),
24 13-19.
- 25 McGillivray, B., Considine, J., 2009. Implementation of evidence into practice: Development of a tool
26 to improve emergency nursing care of acute stroke. *Australasian Emergency Nursing Journal*
27 12 (3), 110-119.
- 28 Miller, D.L., 2016. Acute Stroke: It's All About Process and Team Improving Patient Outcomes in the
29 Emergency Department. *Journal of Radiology Nursing* 35 (3), 198-204.
- 30 Navarrete-Navarro, P., Hart, W.M., Lopez-Bastida, J., Christensen, M.C., 2007. The societal costs of
31 intracerebral hemorrhage in Spain. *Eur J Neurol* 14 (5), 556-562.
- 32 Pandian, J.D., Kaur, A., Jyotsna, R., Sylaja, P.N., Vijaya, P., Padma, M.V., Venkateswaralu, K.,
33 Sukumaran, S., Mathew, R., Kaur, P., Singh, Y.P., Radhakrishnan, K., 2012. Complications in
34 Acute Stroke in India (CAST-I): A Multicenter Study. *Journal of Stroke and Cerebrovascular*
35 *Diseases* 21 (8), 695-703.
- 36 Postmus, D., Pari, A.A., Jaarsma, T., Luttik, M.L., van Veldhuisen, D.J., Hillege, H.L., Buskens, E., 2011.
37 A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure.
38 *Am Heart J* 162 (6), 1096-1104.
- 39 Quinn, B., Baker, D.L., Cohen, S., Stewart, J.L., Lima, C.A., Parise, C., 2014. Basic nursing care to
40 prevent nonventilator hospital-acquired pneumonia. *J Nurs Scholarsh* 46 (1), 11-19.
- 41 Rachapelle, S., Legood, R., Alavi, Y., Lindfield, R., Sharma, T., Kuper, H., Polack, S., 2013. The cost-
42 utility of telemedicine to screen for diabetic retinopathy in India. *Ophthalmology* 120 (3), 566-
43 573.
- 44 Sackley, C., Brittle, N., Patel, S., Ellins, J., Scott, M., Wright, C., Dewey, M.E., 2008. The prevalence of

1 joint contractures, pressure sores, painful shoulder, other pain, falls, and depression in the year
2 after a severely disabling stroke. *Stroke* 39 (12), 3329-3334.

3 Shah, S.V., Corado, C., Bergman, D., Curran, Y., Bernstein, R.A., Naidech, A.M., Prabhakaran, S., 2015.
4 Impact of Poststroke Medical Complications on 30-Day Readmission Rate. *Journal of Stroke*
5 and Cerebrovascular Diseases 24 (9), 1969-1977.

6 Sidhartha, J.M., Purma, A.R., Reddy, L.V.P.K., Sagar, N.K., Teja, M.P., Subbaiah, M.V., Purushothaman,
7 M., 2015. Risk factors for medical complications of acute hemorrhagic stroke. *Journal of Acute*
8 *Disease* 4 (3), 222-225.

9 Sinha, S., Warburton, E.A., 2000. The evolution of stroke units-towards a more intensive approach? *QJM*
10 93 (9), 633-638.

11 Sulch, D., Melbourn, A., Perez, I., Kalra, L., 2002. Integrated care pathways and quality of life on a
12 stroke rehabilitation unit. *Stroke* 33 (6), 1600-1604.

13 The, L.N., 2019. Adding stroke to the political agenda in Europe. *Lancet Neurol* 18 (6), 513.

14 Theofanidis, D., Gibbon, B., 2016. Nursing interventions in stroke care delivery: An evidence-based
15 clinical review. *Journal of Vascular Nursing* 34 (4), 144-151.

16 van Exel, N.J., Koopmanschap, M.A., Scholte, O.R.W., Niessen, L.W., Huijsman, R., 2005. Cost-
17 effectiveness of integrated stroke services. *QJM* 98 (6), 415-425.

18 van Hout, B.A., Al, M.J., Gordon, G.S., Rutten, F.F., 1994. Costs, effects and C/E-ratios alongside a
19 clinical trial. *Health Econ* 3 (5), 309-319.

20 Wang, H., Wang, M., Wang, J., Liu, H., Lu, R., Duan, T., Gong, X., Feng, S., Cui, Z., Liu, Y., Li, C., Ma,
21 J., 2019. Cost-effectiveness analysis of comprehensive intervention programs to control blood
22 glucose in overweight and obese type 2 diabetes mellitus patients based on a real-world setting:
23 Markov modeling. *Annals of translational medicine* 7 (22), 676.

24 Westendorp, W.F., Zock, E., Vermeij, J.D., Kerkhoff, H., Nederkoorn, P.J., Dijkgraaf, M.G.W., van de
25 Beek, D., 2018. Preventive Antibiotics in Stroke Study (PASS): A cost-effectiveness study.
26 *Neurology* 90 (18), e1553-e1560.

27 White, I.R., Royston, P., Wood, A.M., 2011. Multiple imputation using chained equations: Issues and
28 guidance for practice. *Stat Med* 30 (4), 377-399.

29 Who, 2001. Commission on Macroeconomics and Health of WHO. Report on Macroeconomics and
30 Health: Investing in Health for Economic Development. Geneva.

31 Wu, S., Wu, B., Liu, M., Chen, Z., Wang, W., Anderson, C.S., Sandercock, P., Wang, Y., Huang, Y., Cui,
32 L., Pu, C., Jia, J., Zhang, T., Liu, X., Zhang, S., Xie, P., Fan, D., Ji, X., Wong, K.L., Wang, L.,
33 2019. Stroke in China: advances and challenges in epidemiology, prevention, and management.
34 *Lancet Neurol* 18 (4), 394-405.

35 Wu, X., Cai, M., Cao, J., Jiao, J., Liu, G., Li, Z., Liu, Y., 2018. The effects of standardized nursing on
36 improvement of nursing quality among bedridden patients: a multicentered study. *Chinese*
37 *Journal of Nursing* 53 (6), 645-649.

38 Wu, X., Zou, S., Zhu, B., Shi, J., 2015. The hospital costs of stroke patients in Chinese island populations:
39 an 11-year tendency analysis. *J Stroke Cerebrovasc Dis* 24 (5), 988-992.

40 Wunderink, R.G., Waterer, G., 2017. Advances in the causes and management of community acquired
41 pneumonia in adults. *Bmj* 358, j2471.

42 Zhang, X., Li, Z., Cao, J., Jiao, J., Yang, Y., Liu, G., Li, J., Liu, Y., Wu, X., 2016. Current situation of
43 nursing management of common complications in bed ridden patients. *Chinese Nursing*
44 *Management* 16 (4), 433-437.

1 Xie, X., Vondeling, H., 2008. Cost-utility analysis of intensive blood glucose control with metformin
2 versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. *Value*
3 *Health* 11 Suppl 1, S23-32.

4 Yan, T., Liu, C., Li, Y., Xiao, W., Li, Y., Wang, S., 2018. Prevalence and predictive factors of urinary tract
5 infection among patients with stroke: A meta-analysis. *Am J Infect Control* 46 (4), 402-409.

6 Yang, L., Christensen, T., Sun, F., Chang, J., 2012. Cost-effectiveness of switching patients with type 2
7 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model
8 based on the PREDICTIVE study. *Value Health* 15 (1 Suppl), S56-59.

9 Yong, M., Xianjun, X., Jinghu, L., Yunyun, F., 2018. Effect of health insurance on direct hospitalisation
10 costs for in-patients with ischaemic stroke in China. *Aust Health Rev* 42 (1), 39-44.

11

Table 1. Baseline characteristics at the intervention program initiation in the original and the matched cohort.

	Original data			<i>P</i> -value	Matched data			<i>P</i> -value
	Routine Group (n=3891)	Care Group (n=3762)	Intervention Group (n=2966)		Routine Group (n=2966)	Care Group (n=2966)	Intervention Group (n=2966)	
Variables Used for Matching								
Age group, n (%)				0.199				0.887
0-59 years old	1410(36.2)		1292(34.3)		1036(34.9)		1049(35.4)	
60-74 years old	1460(37.5)		1437(38.2)		1138(38.4)		1120(37.8)	
75 years old and above	1021(26.2)		1033(27.5)		792(26.7)		797(26.9)	
Female, n (%)	1659(42.6)		1507(40.1)	0.022	1227(41.4)		1258(42.4)	0.415
Education, n (%)				<0.001				0.586
None	809(20.8)		588(15.6)		508(17.1)		545(18.4)	
Primary school	1218(31.3)		1390(36.9)		1026(34.6)		995(33.5)	
Junior high school	996(25.6)		988(26.3)		765(25.8)		772(26.0)	
High school and above	868(22.3)		796(21.2)		667(22.5)		654(22.0)	
Smoking, n (%)				<0.001				0.578
Never smoke	2708(69.6)		2618(69.6)		2069(69.8)		2079(70.1)	
Ever smoked	936(24.1)		752(20.0)		662(22.3)		673(22.7)	
Smoking now	247(6.3)		392(10.4)		235(7.9)		214(7.2)	
Insurance, n (%)				0.282				0.684
No insurance	766(19.7)		803(21.3)		619(20.9)		647(21.8)	
NCMS	1578(40.6)		1465(38.9)		1131(38.1)		1141(38.5)	
URBMI	666(17.1)		643(17.1)		532(17.9)		504(17.0)	
UEBMI	881(22.6)		851(22.6)		684(23.1)		674(22.7)	
Bedtime, n (%)				<0.001				0.329

1-3 days	1179(30.3)	945(25.1)		800(27.0)	862(29.1)	
4-6 days	695(17.9)	764(20.3)		560(18.9)	532(17.9)	
7-12 days	935(24.0)	982(26.1)		745(25.1)	735(24.8)	
13 days and above	1082(27.8)	1071(28.5)		861(29.0)	837(28.2)	
Experience of ICU, n (%)	978(25.1)	1061(28.2)	0.002	782(26.4)	771(26.0)	0.745
Experience of surgery, n (%)	813(20.9)	821(21.8)	0.321	631(21.3)	621(20.9)	0.750
Respiratory invasive operation within one month, n (%)	108(2.8)	99(2.6)	0.698	82(2.8)	85(2.9)	0.814
Tracheotomy within one month, n (%)	569(14.6)	704(18.7)	<0.001	512(17.3)	496(16.7)	0.580
Urethral invasive operation within one month, n (%)	1154(29.7)	1385(36.8)	<0.001	998(33.6)	973(32.8)	0.491
Number of Charlson comorbidities, n (%)			0.002			0.983
0-3	1217(31.3)	1068(28.4)		881(29.7)	890(30.0)	
4	789(20.3)	719(19.1)		585(19.7)	585(19.7)	
5	934(24.0)	934(24.8)		714(24.1)	718(24.2)	
6 and above	951(24.4)	1041(27.7)		786(26.5)	773(26.1)	
Tertiary hospital, n (%)	2754(70.8)	2511(66.7)	<0.001	2047(69.0)	2050(69.1)	0.933
Province, n (%)			<0.001			0.652
Beijing	177(4.5)	210(5.6)		162(5.5)	170(5.7)	
Sichuan	577(14.8)	591(15.7)		495(16.7)	491(16.6)	
Henan	271(7.0)	257(6.8)		200(6.7)	190(6.4)	
Zhejiang	1461(37.5)	1155(30.7)		957(32.3)	979(33.0)	
Hubei	935(24.0)	842(22.4)		717(24.2)	743(25.1)	
Outcomes Variables						
Total costs	50996(63755)	48641(59882)		51244(64849)	46740(57668)	
QALY (EQ-5D)	0.175(0.087)	0.178(0.085)		0.172(0.088)	0.182(0.084)	

Abbreviations, NCMS: new cooperative medical system; URBMI: urban resident basic medical insurance; UEBMI: urban employee basic medical

insurance; ICU: intensive care unit; QALY: quality-adjusted life year; EQ-5D: EuroQol five-dimensional questionnaire. The Chi-square test was used for balance in the samples.

Table 2. Total costs, QALY gained and ICER of routine care group compared with intervention group in the matched cohort (Imputed data).

	Routine Care Group (n=2966)	Intervention Group (n=2966)	Difference (95% CI)	Adjusted Difference (95% CI)
Total costs	51610	46921	-4689(-7815, -1562)	-4600 (-7050, -2151)
QALY (EQ-5D)	0.170	0.179	0.010(0.005, 0.014)	0.009(0.005, 0.013)
ICER (RMB per QALY gained)	-	-	-480077(-1065860, -141378)	-517011(-1111442, -203912)

Abbreviations, CI: confidence interval; QALY: quality-adjusted life year; EQ-5D: EuroQol five-dimensional questionnaire; ICER: incremental cost-effectiveness ratio. Adjusted difference is from the mixed effects model. 95% CIs for ICERs were bootstrapped.

Figure 1 Five thousand bootstrapped replicates of incremental costs and incremental quality-adjusted life years for intervention group versus routine care group and the resulting cost-effectiveness acceptability curve.




Table 3. Subgroup analysis of the effects of the intervention program on the ICER (Imputed data).

		Routine Care Group	Intervention Group	Difference (95% CI)	Adjusted Difference (95% CI)
Pathological subtypes					
Ischemic	Total costs	41105	35516	-5589(-9107,-2071)	-5402(-8508,-2296)
	QALY (EQ-5D)	0.167	0.179	0.012(0.007, 0.018)	0.011(0.006, 0.016)
	ICER (RMB per QALY gained)	-	-	-459339(-928598, -190814)	-534488(-1102479, -210430)
Hemorrhagic	Total costs	72274	69717	-2557(-8747, 3633)	-3328(-7068, 412)
	QALY (EQ-5D)	0.176	0.181	0.005(-0.003, 0.013)	0.008(0.001, 0.015)
	ICER (RMB per QALY gained)	-	-	-513366(-13069294, 11180594)	-944350(-3922489, 88597)
Hospital levels					
Tertiary hospitals	Total costs	67430	60605	-6825(-10951, -2698)	-9690(-13259, -6120)
	QALY (EQ-5D)	0.171	0.180	0.009(0.003, 0.014)	0.008(0.003, 0.013)
	ICER (RMB per QALY gained)	-	-	-761236(-1940061, -293216)	-1377239(-2987794, -648137)
Non-Tertiary hospitals	Total costs	16270	16301	31(-2085, 2146)	-1466(-4396,1463)
	QALY (EQ-5D)	0.167	0.178	0.011(0.003, 0.019)	0.015(0.008,0.022)
	ICER (RMB per QALY gained)	-	-	2722(-212001, 383822)	-101729(-346392, 107194)

Abbreviations, CI: confidence interval; QALY: quality-adjusted life year; EQ-5D: EuroQol five-dimensional questionnaire; ICER: incremental cost-effectiveness ratio. Adjusted difference is from the mixed effects model. 95% CIs for ICERs were bootstrapped.


Table 4. Sensitivity analysis for impute and propensity score matching techniques

		Routine Care Group	Intervention Group	Difference (95% CI)	Adjusted Difference (95% CI)
Complete cases(n=5039) ^a	Total costs	51263	46729	-4535(-7638.294, 1431.036)	-4557(-6696,-2418)
	QALY (EQ-5D)	0.172	0.182	0.009(0.005, 0.014)	0.009(0.005,0.013)
	ICER (RMB per QALY gained)	-	-	-482437 (-1011852, 156980)	-491635(-952623,-228385)
Mahalanobis distance matching	Total costs	50186	48547	-1639(-5692, 2414)	-1885(-3792,-139)
	QALY (EQ-5D)	0.171	0.179	0.008(0.002, 0.015)	0.007(0.002,0.013)
	ICER (RMB per QALY gained)	-	-	-197790 (-1241662,411912)	-257905(-1190745,-9907)

^a Original data without imputing missing values for the dependent variable (s). Adjusted difference is from the mixed effects model. 95% CIs for ICERs were bootstrapped.

Abbreviations, CI: confidence interval; QALY: quality-adjusted life year; EQ-5D: EuroQol five-dimensional questionnaire; ICER: incremental cost-effectiveness ratio.

Figure 2 Subgroup analysis according to pathological subtypes and hospital levels.



Supplemental On-line Information

Details of the intervention program

Between November 2015 and June 2016, we collected the baseline data in cooperative hospitals, such as the frequency of complications in immobile stroke patients, nursing interventions being implemented for stroke and complications. Therefore, we found that the incidence of four major immobility complications was high (pressure injuries, pneumonia, deep vein thrombosis, urinary tract infections). Meanwhile, an evidence-based searching team consisting of nine master's degree nurses, searched for relevant published papers based on PubMed, ScienceDirect, Embase, etc. with immobile, complications, stroke, pneumonia, pressure injuries, urinary tract infections, etc. as modifiers, then used the Joanna Briggs Institute critical appraisal tools to evaluate the quality of these papers, and extracted effective nursing interventions. In June 2016, based on baseline data and evidence-based search report, 11 expert consultation meetings consisting of 162 nursing specialists with clinical and management background from 6 provinces in China were held. We then constructed the intervention program based on the baseline data, evidence-based results, and expert opinions.

Characteristics of the intervention program

As shown in Supplementary Table 1, there are six elements in the intervention program, including risk factors assessment, observation, nursing precaution, nursing intervention and nursing operation according to complications and health education related to complications. Each element in our program contained critical points, reflecting the knowledge and skills required by nurses to provide standardized nursing care delivery.

Training, data collection and quality control

From August through September in 2016, we trained nurses using our intervention program through on-site centralized teaching and online learning, the trainer were the member of the core research team, who are registered nurse with master's degree, with at least 5 years of clinical working experience and passed the clinical nursing operation exam organized by Peking Union Medical College Hospital, which means the knowledge and clinical nursing operation skills are credible. A total of 12 batches of on-site lectures were organized, and the specific content of the program were taught and tested in the class. We also uploaded the recorded videos of the theoretical lectures that recorded in the class and the nursing operations to an online self-learning platform, in order to help nurses to recall the related knowledge and skills. Between September and October 2016, we pre-tested the program on immobile patients in the 25 hospitals across all six major regions of China to ensure nurses could apply correctly interventions on patients. Finally, we implemented this program formally and collected data between November 2016 and July 2017.

Our study appointed a coordinator who was in charge of internal logistics in each cooperating hospital, and at least two registered head nurses in each ward were designated to oversee patient data collection using a case report form (CRF). To ensure accurate data collection, each nurse received systematic training on completing the CRF before they recorded patients' information daily on the web-based online CRF. From the day of enrolment, all patients were observed and recorded for 90 days, unless there was death in hospital or treatment was abandoned.

Supplementary Table 1 Key points of the intervention program.

Elements	Pressure injuries (PIs)	Deep vein thrombosis (DVT)	Pneumonia	Urinary tract infections (UTIs)
Risk assessment	Identify risk factors by Braden Scale and NRS-2002, pressure area assessment	Identify risk factors by Caprini Risk Assessment Scale	Assess vital signs and risk factors, including swallowing disorders, medical treatments, environmental factors, etc.	Assess gender, age, function and structure of urinary system, iatrogenic factors, immunity factors, metabolic factors and lifestyle behaviors
Observation	Skin surveillance	Limb observation (edema, pain, tenderness, fever, etc.)	Observe lung symptoms and vital signs, etc.	Observe symptoms associated with voiding and vital signs
Precaution	Frequent position changes, use of devices (e.g. apply decompression tool, alternating pressure mattresses, use of padded heel boots)	Daily measurement of calf circumference, mechanical interventions (e.g. plantar arteriovenous pump), drug prevention, etc.	Oral care, prevention of VAP, etc.	Perineal care, possibilities to go to the toilet or sitting upright when urinating
Nursing intervention	Application of pressure reduction dressings, use of devices, change position, etc.	Mechanical interventions, medication care, etc.	Medication care, oral care, mechanical ventilation care, etc.	Medication care, perineal care, catheter maintenance, etc.
Nursing operation	Position changes and replace pressure reduction dressings	Wear off antithrombotic stockings, ankle pump exercise	Respiratory exercises, suctioning, inhalation, postural drainage, etc.	Catheterization, catheter maintenance, hand hygiene, etc.
Health education	Prevention of pressure injuries and home care measures after the occurrence of pressure injuries	Methods of ankle pump exercise and wear antithrombotic stockings, knowledge of using anticoagulant drugs	Knowledge of preventing pneumonia, exercise training of respiratory function, methods of oral feeding, knowledge of using antibiotics	Drink water according to physical condition, do physical activities, methods of perineal care, knowledge of using antibiotics, hand hygiene

Supplementary Table 2 Characteristics between samples with and without missing data

	Without missing data	With missing data	<i>P</i> -value
Age group, n (%)			0.192
0-59 years old	2291(35.3)	411(5.3)	
60-74 years old	2479(38.2)	418(5.9)	
75 years old and above	1719(26.5)	335(8.8)	
Female, n (%)	2703(41.7)	463(9.8)	0.231
Education, n (%)			<0.001
None	1214(18.7)	183(5.7)	
Primary school	2266(34.9)	342(9.4)	
Junior high school	1648(25.4)	336(8.9)	
High school and above	1361(21.0)	303(6.0)	
Smoking, n (%)			0.254
Never smoke	4518(69.6)	808(9.4)	
Ever smoked	1417(21.8)	271(3.3)	
Smoking now	554(8.5)	85(7.3)	
Insurance, n (%)			<0.001
No insurance	1380(21.3)	189(6.2)	
NCMS	2581(39.8)	462(9.7)	
URBMI	1112(17.1)	197(6.9)	
UEBMI	1416(21.8)	316(7.1)	

Bedtime, n (%)			< 0.001
1-3 days	1878(28.9)	246(1.1)	
4-6 days	1241(19.1)	218(8.7)	
7-12 days	1644(25.3)	273(3.5)	
13 days and above	1726(26.6)	427(6.7)	
Experience of ICU, n (%)	1518(23.4)	521(4.8)	< 0.001
Experience of surgery, n (%)	1378(21.2)	256(2.0)	0.562
Respiratory invasive operation within one month, n (%)	151(3)	56(4.8)	< 0.001
Tracheotomy within one month, n (%)	998(5.4)	275(3.6)	< 0.001
Urethral invasive operation within one month, n (%)	2008(30.9)	531(5.6)	< 0.001
Number of Charlson comorbidities, n (%)			
0-3	1931(29.8)	354(0.4)	0.399
4	1277(19.7)	231(9.8)	
5	1606(24.7)	262(2.5)	
6 and above	1675(25.8)	317(7.2)	
Tertiary hospital, n (%)	4338(66.9)	927(9.6)	< 0.001
Province, n (%)			< 0.001
Beijing	327(5.0)	60(5.2)	
Sichuan	1007(15.5)	161(3.8)	
Henan	318(4.9)	210(8.0)	
Zhejiang	2321(35.8)	295(5.3)	
Hubei	1644(25.3)	133(1.4)	

Abbreviations, NCMS: new cooperative medical system; URBMI: urban resident basic

medical insurance; UEBMI: urban employee basic medical insurance; ICU: intensive care unit.